Cibc World Market Inc. raised its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 70.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,668 shares of the medical instruments supplier’s stock after purchasing an additional 11,874 shares during the quarter. Cibc World Market Inc.’s holdings in West Pharmaceutical Services were worth $10,629,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of West Pharmaceutical Services during the second quarter worth $2,387,990,000. State Street Corp grew its holdings in shares of West Pharmaceutical Services by 1.7% during the second quarter. State Street Corp now owns 3,348,698 shares of the medical instruments supplier’s stock valued at $1,202,183,000 after buying an additional 54,920 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at $733,733,000. Generation Investment Management LLP acquired a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at $728,168,000. Finally, Aberdeen Group plc increased its position in shares of West Pharmaceutical Services by 2,283.1% in the 3rd quarter. Aberdeen Group plc now owns 1,462,033 shares of the medical instruments supplier’s stock valued at $542,063,000 after acquiring an additional 1,400,682 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on WST shares. Jefferies Financial Group restated a “buy” rating and issued a $475.00 target price on shares of West Pharmaceutical Services in a research note on Monday, November 2nd. Barclays boosted their price target on West Pharmaceutical Services from $440.00 to $500.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. UBS Group raised their price objective on West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, Evercore restated an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $424.67.
View Our Latest Stock Analysis on West Pharmaceutical Services
West Pharmaceutical Services Price Performance
NYSE:WST opened at $390.36 on Friday. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $438.27. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.10 and a current ratio of 2.82. The firm has a market cap of $27.19 billion, a price-to-earnings ratio of 43.81, a PEG ratio of 2.54 and a beta of 1.13. The firm’s fifty day moving average is $386.67 and its two-hundred day moving average is $325.12.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. The business had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business posted $1.96 EPS. Research analysts expect that West Pharmaceutical Services, Inc. will post 9.44 EPS for the current year.
West Pharmaceutical Services Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th were issued a $0.26 dividend. The ex-dividend date of this dividend was Tuesday, November 10th. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. This represents a $1.04 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is presently 11.67%.
More West Pharmaceutical Services News
Investors following WST have been watching these news items:
- Positive Sentiment: Zacks also increased estimates for multiple quarters through 2028, including Q3 2028 to $2.82 from $2.69 and Q2 2028 to $3.02 from $2.83. Broad upward revisions could support sentiment toward WST.
- Neutral Sentiment: Zacks maintained a “Hold” rating, tempering the signal from its higher earnings forecasts.
- Negative Sentiment: A recent Zacks analysis cited near-term headwinds, despite longer-term support from high-value product demand, biologics exposure and regulatory upgrades. Article: Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Insider Transactions at West Pharmaceutical Services
In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the sale, the vice president owned 16,845 shares in the company, valued at approximately $5,740,944.45. This represents a 32.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 15,659 shares of company stock valued at $5,443,749 over the last three months. Insiders own 0.60% of the company’s stock.
West Pharmaceutical Services Profile
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
See Also
- Five stocks we like better than West Pharmaceutical Services
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
